Evidence map›Paper›PMID 39444852›Full record

ArticleJournal of thoracic disease2024

The efficacy and safety of herbal formulas for adults with pulmonary hypertension combined with chronic obstructive pulmonary disease: a systematic review and meta-analysis involving 1,865 participants.

Rui Liang, Dong Liu, Haobo Li, Yue Yan, Wanmu Xie, Zhenguo Zhai

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui Liang *Beijing University of Chinese Medicine China-Japan Friendship School of Clinical Medicine, Beijing, China.ORCID https://orcid.org/0000-0003-0046-2064
Dong Liu *National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Haobo LiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Yue YanNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Integrative Pulmonary Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Wanmu XieBeijing University of Chinese Medicine China-Japan Friendship School of Clinical Medicine, Beijing, China.
Zhenguo ZhaiBeijing University of Chinese Medicine China-Japan Friendship School of Clinical Medicine, Beijing, China.ORCID https://orcid.org/0000-0002-7096-8792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is currently no effective treatment for the majority of patients with chronic obstructive pulmonary disease combined with pulmonary hypertension (COPD-PH). Numerous clinical trials have demonstrated the use of traditional Chinese medicine (TCM) herbal formulas in combination with routine western pharmacotherapy (WP) for the treatment of COPD-PH, with positive results. This meta-analysis was designed to evaluate the efficacy and safety of TCM herbal formulas in the treatment of COPD-PH. Methods: A systematic literature search was conducted using Web of Science, PubMed, Chinese National Knowledge Infrastructure (CNKI), WanFang, and Chinese Science and Technology Journal (VIP) from database inception until October 2023. The primary outcome was pulmonary artery pressure parameters, including pulmonary artery systolic pressure (PASP) and mean pulmonary artery pressure (mPAP). Secondary outcomes included pulmonary ventilation function parameters, such as forced expiratory volume in one second (FEV1) and the ratio of FEV1 to forced vital capacity (FEV1/FVC%), as well as functional capacity assessments measured by the six-minute walk distance (6MWD). Reviewer Manager software was used for both random-effects and fixed-effects meta-analyses. We registered the protocol for this study with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY, registry number: INPLASY2022100041). Results: Twenty randomized control trials with a total of 1,865 patients were included in the meta-analysis. The results of our meta-analysis revealed that TCM herbal formulas in combination with basic WP significantly reduced pulmonary artery pressure in patients with COPD-PH, including PASP [mean difference (MD) =-4.50 mmHg, 95% confidence interval (CI): -6.04, -2.95] and mPAP (MD =-4.47 mmHg, 95% CI: -5.07, -3.88). Additionally, pulmonary ventilation function and 6MWD (MD =48.13 m, 95% CI: 39.92, 56.34) were also improved in COPD-PH patients. Pulmonary ventilation function was reflected by FEV1 (MD =0.83 L, 95% CI: 0.35, 1.30) and FEV1/FVC% (MD =4.76, 95% CI: 3.75, 5.77). A total of six studies reported adverse events in detail, and all claimed that no adverse events were observed in COPD-PH patients using TCM herbal formulas. Conclusions: The combination of TCM herbal formulas and basic WP might be more effective in improving the quality of life and exercise capacity of patients with COPD-PH than basic WP alone. However, the firm conclusions of our study were hampered by the low quality of the evidence.

Indexed as

chronic obstructive pulmonary disease (COPD)meta-analysispulmonary hypertension (PH)Traditional Chinese medicine (TCM)

Identifiers

PMID39444852
PMCPMC11494573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.